Skip to content

Retrospective Modulus ALIF Study

An Assessment of the Safety and Performance of the Modulus® ALIF System in Patients Undergoing Anterior Lumbar Interbody Fusion

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05566704
Enrollment
123
Registered
2022-10-04
Start date
2022-08-18
Completion date
2024-05-01
Last updated
2025-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Degenerative Disc Disease, Spondylolisthesis, Stenosis

Brief summary

The primary objective of this study is to evaluate the safety and performance of the Modulus ALIF System in patients undergoing anterior lumbar interbody fusion (ALIF) as measured by reported complications, radiographic outcomes, and patient-reported outcomes.

Detailed description

Patients considered for this study will have previously undergone surgery for their spinal condition according to the standard of care of the practitioner. All patients at a given site who meet eligibility requirements will be considered for participation in the study. Available progress notes, medical records, patient-reported outcomes, radiographs (plain film and CT scans, if available), and complications will be obtained from the medical records of all enrolled subjects. The complication profile and overall performance of the Modulus ALIF System will be assessed using the following: 1. Complications attributable to the use of the Modulus ALIF System as noted in surgical summaries, progress notes, and hospital records; and 2. Radiographic outcome (fusion) and description of device status from available plain film radiographs and CT scan(s); and 3. Neurologic status, symptoms, and/or subject self-reported clinical outcomes (e.g., pain and disability), as available

Interventions

DEVICEModulus ALIF System

The Modulus ALIF System is designed to address lumbar pathologies utilizing interbody placement through an anterior or anterolateral surgical approach. The Modulus ALIF System is an interfixated interbody system available in various shapes and sizes to suit the individual pathology and anatomical conditions of the patient.

Sponsors

NuVasive
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

1. Availability of progress notes and radiographic information preoperatively and a minimum of 6 months following surgery 2. Male or female patients who are ≥18 years of age at the time of surgery 3. Had undergone a regiment of at least six (6) months of nonoperative care treatment prior to being treated with the Modulus ALIF system, except in patients with progressive neurological deficits, neurogenic claudication causing significant disability, or developed cauda equine syndrome 4. Treated with ALIF procedure with the Modulus ALIF System at: * One or two adjacent lumbar and/or lumbosacral levels for degenerative disc disease (DDD), degenerative spondylolisthesis, or spinal stenosis, or * Any number of lumbar and/or lumbosacral levels for degenerative scoliosis (defined as \>10º coronal curve) or sagittal deformity 5. Supplemental fixation cleared by the applicable regulatory body for use in the thoracolumbar spine unless the procedure meets all of the following criteria: * 1-2 levels treated for DDD, and * 3 or 4 interfixated screws placed, and * Implant lordosis is ≤20°

Exclusion criteria

1. Patient was a prisoner at the time of Modulus ALIF treatment 2. Patient was participating in another clinical study during treatment that would confound study data

Design outcomes

Primary

MeasureTime frame
Rates of complications attributable to the use of the Modulus ALIF System12 months
Proportion of subjects with apparent radiographic fusion at 6 months or greater postoperative12 months

Secondary

MeasureTime frame
Change in neurologic status, symptoms, and/or subject self-reported clinical outcomes (e.g., pain and disability), as available12 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026